[{"id":"903768d6-1c26-467f-9215-aec394001ea9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05433480","created_at":"2022-06-27T14:54:25.302Z","updated_at":"2024-07-02T16:35:41.905Z","phase":"Phase 3","brief_title":"A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer","source_id_and_acronym":"NCT05433480","lead_sponsor":"Betta Pharmaceuticals Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Konmana (tibremciclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 274","initiation":"Initiation: 05/25/2022","start_date":" 05/25/2022","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2023-07-27"}]